

To: (10)(2e)@lists.european-virus-archive.com; (10)(2e)@lists.european-virus-archive.com; (10)(2e)  
 (10)(2e)@lists.european-virus-archive.com; (10)(2e)@lists.european-virus-archive.com]  
 From: Contact-partners  
 Sent: Tue 8/4/2020 8:35:11 AM  
 Subject: Re: [EVA Global : Contact-partners] COVID19 & the Nagoya Protocol: benefit sharing survey (last day!!)  
 Received: Tue 8/4/2020 8:37:49 AM  
[ATT00001.txt](#)

Dear all,

gentle reminder that **today** is the last day to fill out our [survey](#) to quantify the international collaboration (benefit sharing) supporting the global response to the COVID-19 pandemic.

With warm regards,

WP7 team

PS -- Please feel free to forward on to colleagues outside of EVA-GLOBAL that are involved with the international COVID-19 response: <https://evaglobalcovid19.limequery.com/782238?lang=en>

On 08.07.20 11:04, (10)(2e) via Contact-partners wrote:

Dear EVA-GLOBAL members and associated partners,

As you might remember, a few years ago the EVA-GLOBAL consortium and the Bernard Nocht Institute were mentioned in a [Third World Network](#) and [Telegraph article](#) linked to unfounded biopiracy allegations around an Ebola outbreak. We are concerned the same political strategy could now be employed in the near future around the COVID19 pandemic in which EVA-GLOBAL has played a critical role. Indeed, a letter to the UN Secretary General from a group of [NGOs](#) (also organized by the Third World Network) citing concerns that developed nations might not fairly share future benefits from COVID19 research (e.g. medicines, vaccines) with developing countries could be the first inkling.

We share the concerns expressed in the letter regarding social justice and inequality issues, but also believe benefit-sharing through research is often overlooked. As discussed at the EVA General Assembly in February, we want to engage in this issue and publish an open letter that explores this tension between use of SARS-CoV-2 material and sequence data, benefit sharing, the Nagoya Protocol, and biopiracy allegations.

To do this, we need your help. **WP7 has created a [survey](#) to quantify the international collaboration (benefit sharing) supporting the global response to the COVID-19 pandemic. Before going to your well-deserved summer holidays (by August 5<sup>th</sup>) please fill it out.**

Thank you for your support!

With warm regards,

(10)(2e)

PS -- Please forward on to colleagues outside of EVA-GLOBAL that are involved with the international COVID-19 response: <https://evaglobalcovid19.limequery.com/782238?lang=en>

--

(10)(2e)

(10)(2e)

(10)(2e)  
Leibniz-Institut DSMZ German Collection of Microorganisms and Cell Cultures  
Inhoffenstraße 7 B 38124 Braunschweig Germany  
Tel. ++49- (10)(2e)  
[www.dsmz.de](http://www.dsmz.de)

Geschäftsführung: (10)(2e)  
(10)(2e)  
Vorsitzender des Aufsichtsrats: (10)(2e)  
Die DSMZ ist Mitglied der Leibniz-Gemeinschaft  
[www.leibniz-gemeinschaft.de](http://www.leibniz-gemeinschaft.de)

Contact-partners mailing list at European Virus Archive Global  
(10)(2e) [@lists.european-virus-archive.com](mailto:@lists.european-virus-archive.com)

--  
(10)(2e) (10)(2e) (10)(2e)  
EVA-GLOBAL project

Leibniz Institute - DSMZ German Collection of Microorganisms and Cell Cultures GmbH  
Inhoffenstraße 7B  
38124 Braunschweig  
GERMANY

Tel. +49- (10)(2e)  
Fax +49- (10)(2e)  
(10)(2e) [@dsmz.de](mailto:@dsmz.de)